The Deferasirox–AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Host iron availability is fundamental to mucormycosis pathogenesis. The combination of liposomal amphotericin B (LAmB) and deferasirox iron chelation therapy synergistically improved survival in diabetic mice with mucormycosis. To determine the safety of combination deferasirox plus LAmB therapy for mucormycosis, a multicentred, placebo-controlled, double-blinded clinical trial was conducted. METHODS: Twenty patients with proven or probable mucormycosis were randomized to receive treatment with LAmB plus deferasirox (20 mg/kg/day for 14 days) or LAmB plus placebo (NCT00419770, clinicaltrials.gov). The primary analyses were for safety and exploratory efficacy. RESULTS: Patients in the deferasirox arm (n=11) were more likely than those in the placebo arm (n=9) to have active malignancy, neutropenia and corticosteroid therapy, and were less likely to receive concurrent non-study antifungal therapy. Reported adverse events and serious adverse events were similar between the groups. However, death was more frequent in the deferasirox than in the placebo arm at 30 days (45% versus 11%, P=0.1) and 90 days (82% versus 22%, P=0.01). Global success (alive, clinically stable, radiographically improved) for the deferasirox arm versus the placebo arm at 30 and 90 days, respectively, was 18% (2/11) versus 67% (6/9) (P=0.06) and 18% (2/11) versus 56% (5/9) (P=0.2). CONCLUSIONS: Patients with mucormycosis treated with deferasirox had a higher mortality rate at 90 days. Population imbalances in this small Phase II study make generalizable conclusions difficult. Nevertheless, these data do not support a role for initial, adjunctive deferasirox therapy for mucormycosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, in a prospective RCT, the addition of DFX to patients with proven or probable mucormycosis treated with antifungal liposomal amphotericin B increased the mortality (Spellberg et al., 2011).”
From Iron in infection and immunity (2020) · cites this paper as Spellberg et al., 2011
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, a recent clinical trial in patients after allogenic bone marrow transplantation who received the iron chelator desferrasirox in an attempt to improve the control of mucormycosis, a devastating invasive fungal infection in severely immuno-compromised patients, failed to show a clinical benefit (Spellberg et al., 2012).”
From Iron at the interface of immunity and infection (2014) · cites this paper as Spellberg et al., 2012
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The sample size was small in this RCT and confounders may have been present, leaving open questions but DFX may lack beneficial effects in mucormycosis.”
From Iron in infection and immunity (2020) · cites this paper as Spellberg et al., 2011
The cited source says what the claim attributes to it.
In the citing paper
“The sample size was small in this RCT and confounders may have been present, leaving open questions but DFX may lack beneficial effects in mucormycosis.”
From Iron in infection and immunity (2020) · cites this paper as Spellberg et al., 2011
In the citing paper
“However, a small, multicenter clinical study using desferasirox as an adjunct treatment in patients that develop mucormycosis after allogeneic bone marrow transplantation resulted in a rather unfavorable outcome, for reasons that are not clear [28].”
From The Iron age of host–microbe interactions (2015) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases
Roden, M. M., Zaoutis, T. E., Buchanan, W. L., Knudsen, T. A., Sarkisova, T. A., Schaufele, R. L., Sein, M., Sein, T., Chiou, C. C., Chu, J. H., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/432579 · Cited by 3,044
Self-citationAscioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331
Chamilos, G., Lewis, R. E., & Kontoyiannis, D. P. (2008) · Clinical Infectious Diseases · doi:10.1086/590004 · Cited by 826
Self-citationRecent Advances in the Management of Mucormycosis: From Bench to Bedside
Spellberg, B., Walsh, T. J., Kontoyiannis, D. P., Edwards, Jr., & Ibrahim, A. S. (2009) · Clinical Infectious Diseases · doi:10.1086/599105 · Cited by 548
Self-citationIncreasing Incidence of Zygomycosis (Mucormycosis), France, 1997–2006
Bitar, D., Van Cauteren, D., Lanternier, F., Dannaoui, E., Che, D., Dromer, F., Desenclos, J.-C., & Lortholary, O. (2009) · Emerging Infectious Diseases · doi:10.3201/eid1509.090334 · Cited by 429
Artis, W. M., Fountain, J. A., Delcher, H. K., & Jones, H. E. (1982) · Diabetes · doi:10.2337/diabetes.31.12.1109 · Cited by 369
Boelaert, J. R., de Locht, M., Van Cutsem, J., Kerrels, V, Cantinieaux, B., Verdonck, A., Van Landuyt, H. W., & Schneider, Y. J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116419 · Cited by 340
Nisbet-Brown, E., Olivieri, N. F., Giardina, P. J., Grady, R. W., Neufeld, E. J., Séchaud, R., Krebs-Brown, A. J., Anderson, J. R., Alberti, D., Sizer, K. C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13309-0 · Cited by 328
The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice
Liu, M., Spellberg, B., Phan, Q. T., Fu, Y., Fu, Y., Lee, A. S., Edwards, J. E., Filler, S. G., & Ibrahim, A. S. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42164 · Cited by 324
Self-citationThe iron chelator deferasirox protects mice from mucormycosis through iron starvation
Ibrahim, A. S., Gebermariam, T., Fu, Y., Lin, Husseiny, M. I., French, S. W., Schwartz, J., Skory, C. D., Edwards, J. E., & Spellberg, B. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32338 · Cited by 308
Self-citation
Cited by
Global Epidemiology of Mucormycosis
Prakash, H., & Chakrabarti, A. (2019) · Journal of Fungi · doi:10.3390/jof5010026 · Cited by 938
“Thus, the study did not support the use of deferasirox as an adjuvant therapy in the treatment of mucormycosis, though patients under deferasirox treated arm had higher morbidity [90].”
ResultESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013
Cornely, O. A., Arikan-Akdagli, S., Dannaoui, E., Groll, A. H., Lagrou, K., Chakrabarti, A., Lanternier, F., Pagano, L., Skiada, A., Akova, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12371 · Cited by 863
Tissot, F., Agrawal, S., Pagano, L., Petrikkos, G., Groll, A. H., Skiada, A., Lass-Flörl, C., Calandra, T., Viscoli, C., & Herbrecht, R. (2017) · Haematologica · doi:10.3324/haematol.2016.152900 · Cited by 682
“The ECIL-3 recommendations for the treatment of mucormycosis were mostly based on retrospective studies, registry data and small prospective non-controlled studies.(3,68-77) Few new data are available for the treatment of mucormycosis since the ECIL 4 and, therefore, the current recommendations are very similar (Table…”
MethodChallenges in the diagnosis and treatment of mucormycosis
Skiada, A., Lass-Floerl, C., Klimko, N., Ibrahim, A., Roilides, E., & Petrikkos, G. (2018) · Medical Mycology · doi:10.1093/mmy/myx101 · Cited by 568
Self-citationStone, N. R. H., Bicanic, T., Salim, R., & Hope, W. (2016) · Drugs · doi:10.1007/s40265-016-0538-7 · Cited by 537
“Early surgical intervention may be just as important as the use of an effective antifungal agent [93].”
Patel, A., Kaur, H., Xess, I., Michael, J. S., Savio, J., Rudramurthy, S., Singh, R., Shastri, P., Umabala, P., Sardana, R., et al. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.11.021 · Cited by 405
Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT)
Cappellini, M. D., Cohen, A. R., Porter, J. B., Taher, A. T., & Viprakasit, V. (2014) · Cited by 726
Skiada, A., Lanternier, F., Groll, A. H., Pagano, L., Zimmerli, S., Herbrecht, R., Lortholary, O., Petrikkos, G. L., & Leukemia*, O. B. O. T. T. E. C. O. I. I. (2013) · Haematologica · doi:10.3324/haematol.2012.065110 · Cited by 372
“A double-blinded, randomized, placebo-controlled phase II clinical trial of the safety and exploratory efficacy of adjunctive deferasirox therapy for patients with mucormycosis treated with L-AmB (the deferasirox-AmBisome therapy for mucormycosis (DEFEAT Mucor) study; NCT00419770) failed to demonstrate any benefit fro…”
The Changing Epidemiology of Invasive Fungal Infections
Enoch, D. A., Yang, H., Aliyu, S. H., & Micallef, C. (2017) · Methods in Molecular Biology · doi:10.1007/978-1-4939-6515-1_2 · Cited by 370
Iron in infection and immunity
Nairz, M., & Weiss, G. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100864 · Cited by 359
Iron at the interface of immunity and infection
Nairz, M., Haschka, D., Demetz, E., & Weiss, G. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00152 · Cited by 325
CotH3 mediates fungal invasion of host cells during mucormycosis
Gebremariam, T., Liu, M., Luo, G., Bruno, V., Phan, Q. T., Waring, A. J., Edwards, J. E., Filler, S. G., Yeaman, M. R., & Ibrahim, A. S. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71349 · Cited by 254
“L. corymbifera is also a clinical isolate obtained from the DEFEAT Mucor clinical study (38).”
Self-citationAn overview of infectious complications after allogeneic hematopoietic stem cell transplantation
Sahin, U., Toprak, S. K., Atilla, P. A., Atilla, E., & Demirer, T. (2016) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2016.05.006 · Cited by 252
Invasive fungal infections in solid organ transplant recipients
Gavaldà, J., Meije, Y., Fortún, J., Roilides, E., Saliba, F., Lortholary, O., Muñoz, P., Grossi, P., & Cuenca-Estrella, M. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12660 · Cited by 232
“A triple therapy using lipid amphotericin B, micafungin and deferasirox was effective in a murine model of mucormycosis [163], but not in patients [164].”
BackgroundThe Iron age of host–microbe interactions
Soares, M. P., & Weiss, G. (2015) · The EMBO Reports · doi:10.15252/embr.201540558 · Cited by 227
“However, a small, multicenter clinical study using desferasirox as an adjunct treatment in patients that develop mucormycosis after allogeneic bone marrow transplantation resulted in a rather unfavorable outcome, for reasons that are not clear [28].”
Muthu, V., Rudramurthy, S. M., Chakrabarti, A., & Agarwal, R. (2021) · Mycopathologia · doi:10.1007/s11046-021-00584-8 · Cited by 225
Mucormycosis in Organ and Stem Cell Transplant Recipients
Lanternier, F., Sun, H.-Y., Ribaud, P., Singh, N., Kontoyiannis, D. P., & Lortholary, O. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis195 · Cited by 212
Self-citationMolecular mechanisms of mucormycosis—The bitter and the sweet
Baldin, C., & Ibrahim, A. S. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006408 · Cited by 212
Self-citationMold Infections of the Central Nervous System
McCarthy, M., Rosengart, A., Schuetz, A. N., Kontoyiannis, D. P., & Walsh, T. J. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1216008 · Cited by 203
Self-citationSoliman, G. M. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.03.019 · Cited by 203
“…et al. (2012) Febrile neutropenia 3 mg/kg/d Human Caselli et al. (2012) Mucormycosis 5 mg/kg thrice weekly plus 20 mg/kg/d of Deferasirox1 Human Spellberg et al. (2012) Antifungal prophylaxis in patients with expected neutropenia nebulized liposomes (12.5 mg for 4 d then twice weekly until…”
BackgroundInfluentialFarmakiotis, D., & Kontoyiannis, D. P. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.011 · Cited by 200
Self-citationInvasive Mold Infections Following Combat-related Injuries
Warkentien, T., Rodriguez, C., Lloyd, B., Wells, J., Weintrob, A., Dunne, J. R., Ganesan, A., Li, P., Bradley, W., Gaskins, L. J., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis749 · Cited by 190
Sipsas, N. V., Gamaletsou, M. N., Anastasopoulou, A., & Kontoyiannis, D. P. (2018) · Journal of Fungi · doi:10.3390/jof4030090 · Cited by 183
“However, a subsequent prospective, randomized study in patients with hematologic malignancies showed that the combination of LAMB with deferasirox was associated with increased mortality [99].”
BackgroundSelf-citationLanternier, F., Poiree, S., Elie, C., Garcia-Hermoso, D., Bakouboula, P., Sitbon, K., Herbrecht, R., Wolff, M., Ribaud, P., & Lortholary, O. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv236 · Cited by 182
Rhinocerebral Mucormycosis and COVID-19 Pneumonia
Alekseyev, K., Didenko, L., & Chaudhry, B. (2021) · Journal of Medical Cases · doi:10.14740/jmc3637 · Cited by 177
“Once that is established, you can send for susceptibility [2, 6].”
BackgroundInfluentialMucormycosis: its contemporary face and management strategies
Sun, H.-Y., & Singh, N. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70316-9 · Cited by 175
Combination Therapy for Mucormycosis: Why, What, and How?
Spellberg, B., Ibrahim, A., Roilides, E., Lewis, R. E., Lortholary, O., Petrikkos, G., Kontoyiannis, D. P., & Walsh, T. J. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir885 · Cited by 171
Self-citationSteinbrink, J. M., & Miceli, M. H. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.009 · Cited by 166
Diabetes and mucormycosis: A complex interplay
Rammaert, B., Lanternier, F., Poirée, S., Kania, R. E., & Lortholary, O. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.01.002 · Cited by 175
“Unfortunately, a double-blinded, andomized, placebo-controlled, phase II clinical trial — the eferasirox-AmBisome Therapy for Mucormycosis (DEFEAT ucor) study — failed to demonstrate a benefit of adjunctive eferasirox therapy to LAmB for mucormycosis [115].”
BackgroundMucormycosis in 2023: an update on pathogenesis and management
Alqarihi, A., Kontoyiannis, D. P., & Ibrahim, A. S. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1254919 · Cited by 181
Self-citationMucormycosis of the Central Nervous System
Chikley, A., Ben‐Ami, R., & Kontoyiannis, D. P. (2019) · Journal of Fungi · doi:10.3390/jof5030059 · Cited by 155
“The primary outcome of response at week four occurred in 36% of patients, similar to the 40% global response observed in the DEFEAT study, where the protocol defined l-AmB dose was ≥5 mg/kg thrice weekly (see below) [112].”
BackgroundMethodResultInfluentialSelf-citationMaschmeyer, G., Carratalà, J., Buchheidt, D., Hamprecht, A., Heussel, C. P., Kahl, C., Lorenz, J., Neumann, S., Rieger, C., Ruhnke, M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu192 · Cited by 145
“A combination of liposomal amphotericin B and the iron chelator deferasirox for the treatment of mucormycoses has shown inferior clinical results for the combination when compared with the antifungal agent alone [151].”
ResultMucormycosis treated with posaconazole: review of 96 case reports
Vehreschild, J. J., Birtel, A., Vehreschild, M. J. G. T., Liss, B., Farowski, F., Kochanek, M., Sieniawski, M. K., Steinbach, A., Wahlers, K., Fätkenheuer, G., et al. (2012) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2012.711741 · Cited by 154
“Preclinical data strongly suggest that the combination with an (otherwise ineffective) echinocandin might also be beneficial (Ibrahim et al., 2003; Spellberg et al., 2005b, 2012a; Reed et al., 2008; Gleissner et al., 2004).”
BackgroundResultClinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B
Groll, A. H., Rijnders, B. J. A., Walsh, T. J., Adler‐Moore, J., Lewis, R. E., & Brüggemann, R. J. M. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz076 · Cited by 153
Fungal iron homeostasis with a focus on Aspergillus fumigatus
Misslinger, M., Hortschansky, P., Brakhage, A. A., & Haas, H. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118885 · Cited by 154
Update on mucormycosis pathogenesis
Ibrahim, A. S., & Kontoyiannis, D. P. (2013) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000008 · Cited by 146
Self-citationVaughan, C., Bartolo, A., Vallabh, N., & Leong, S. C. (2018) · Clinical Otolaryngology · doi:10.1111/coa.13175 · Cited by 144
“papers contained multiple case reports).(4-142) Larger case series were usually excluded due to a lack of chronological data (refer to Figure 1 for PRISMA flow diagram).”
BackgroundEpidemiology and Treatment of Mucormycosis
Lewis, R. E., & Kontoyiannis, D. P. (2013) · Future Microbiology · doi:10.2217/fmb.13.78 · Cited by 128
Self-citationMucormycosis treatment: Recommendations, latest advances, and perspectives
Brunet, K., & Rammaert, B. (2020) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2020.101007 · Cited by 151
Cerebro-rhino orbital mucormycosis: An update
Wali, U., Balkhair, A., & Al-Mujaini, A. S. (2012) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2012.01.003 · Cited by 138
Antifungal resistance in mucorales
Dannaoui, É. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.08.010 · Cited by 132
Risk factors for mortality in patients with mucormycosis
Spellberg, B. J., Kontoyiannis, D. P., Fredricks, D. N., Morris, M. I., Perfect, J. R., Chin-Hong, P. V., Ibrahim, A. S., & Brass, E. P. (2012) · Medical Mycology · doi:10.3109/13693786.2012.669502 · Cited by 127
“More recently, the results of the first randomized, controlled trial of patients with mucormycosis were reported (10).”
BackgroundSelf-citationBicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis
Gebremariam, T., Lin, L., Liu, M., Kontoyiannis, D. P., French, S., Edwards, J. E., Filler, S. G., & Ibrahim, A. S. (2016) · Journal of Clinical Investigation · doi:10.1172/jci82744 · Cited by 120
Self-citationJeong, W., Keighley, C., Wolfe, R. S., Lee, W. L., Slavin, M. A., Chen, S. C. ‐., & Kong, D. C. M. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.01.002 · Cited by 130
GRP78 and Integrins Play Different Roles in Host Cell Invasion during Mucormycosis
Alqarihi, A., Gebremariam, T., Gu, Y., Swidergall, M., Alkhazraji, S., Soliman, S. S. M., Bruno, V. M., Edwards, J. E., Filler, S. G., Uppuluri, P., et al. (2020) · mBio · doi:10.1128/mbio.01087-20 · Cited by 121
“Lichtheimia corymbifera strain 008-0490 and Rhizomucor were collected from patients enrolled in the The Deferasirox-AmBisome Therapy for Mucormycosis study (DEFEAT Mucormycosis) (44), Cunninghamella bertholletiae 182 is a clinical isolate obtained from Dr. Thomas Walsh, (NIH, Bethesda, Maryland, USA).”
MethodSelf-citationIron and innate antimicrobial immunity-depriving the pathogen, defending the host
Nairz, M., Dichtl, S., Schroll, A., Haschka, D., Tymoszuk, P., Theurl, I., & Weiss, G. (2018) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2018.03.007 · Cited by 123
Role of divalent metals in infectious disease susceptibility and outcome
Weiss, G., & Carver, P. L. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.01.018 · Cited by 123
Infections in myelodysplastic syndromes
Toma, A., Fenaux, P., Dreyfus, F., & Cordonnier, C. (2012) · Haematologica · doi:10.3324/haematol.2012.063420 · Cited by 133
Pagano, L., Cornely, O. A., Busca, A., Caira, M., Cesaro, S., Gasbarrino, C., Girmenia, C., Heinz, W. J., Herbrecht, R., Lass-Florl, C., et al. (2013) · Haematologica · doi:10.3324/haematol.2012.083063 · Cited by 121
Jenks, J. D., Salzer, H. J., Prattes, J., Krause, R., Buchheidt, D., & Hoenigl, M. (2018) · Drug Design, Development and Therapy · doi:10.2147/dddt.s145545 · Cited by 114
“60 In the AmBizygo study, a single-arm Phase II trial, 34 patients were treated with 10 mg/kg per day of lipAmB for disseminated mucormycosis.”
PCR-Based Approach Targeting Mucorales-Specific Gene Family for Diagnosis of Mucormycosis
Baldin, C., Soliman, S. S. M., Jeon, H. H., Alkhazraji, S., Gebremariam, T., Gu, Y., Bruno, V. M., Cornely, O. A., Leather, H. L., Sugrue, M. W., et al. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.00746-18 · Cited by 120
Self-citationMucoricin is a ricin-like toxin that is critical for the pathogenesis of mucormycosis
Soliman, S. S. M., Baldin, C., Gu, Y., Singh, S., Gebremariam, T., Swidergall, M., Alqarihi, A., Youssef, E. G., Alkhazraji, S., Pikoulas, A., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-020-00837-0 · Cited by 112
Self-citationMikasa, K., Aoki, N., Aoki, Y., Abe, S., Iwata, S., Ouchi, K., Kasahara, K., Kadota, J., Kishida, N., Kobayashi, O., et al. (2016) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2015.12.019 · Cited by 121
“- Combination therapy with an iron chelating agent and L-AMB should be avoided [181] (AI).”
Mucormycosis: risk factors, diagnosis, treatments, and challenges during COVID-19 pandemic
Sharma, A., & Goel, A. (2022) · Folia Microbiologica · doi:10.1007/s12223-021-00934-5 · Cited by 126
Leal, S. M., Roy, S., Vareechon, C., Carrion, S. D., Clark, H., Lopez-Berges, M. S., diPietro, A., Schrettl, M., Beckmann, N., Redl, B., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003436 · Cited by 111
“However, the trial was unsuccessful due to an unexpected increased risk of death in patients receiving deferasirox adjunct therapy [61].”
BackgroundBlyth, C. C., Gilroy, N. M., Guy, S., Chambers, S. T., Cheong, E. Y. L., Gottlieb, T., McGuinness, S. L., & Thursky, K. (2014) · Internal Medicine Journal · doi:10.1111/imj.12598 · Cited by 118
pH Signaling in Human Fungal Pathogens: a New Target for Antifungal Strategies
Cornet, M., & Gaillardin, C. (2014) · Eukaryotic Cell · doi:10.1128/ec.00313-13 · Cited by 98
Therapeutic Challenges of Non- Aspergillus Invasive Mold Infections in Immunosuppressed Patients
Lamoth, F., & Kontoyiannis, D. P. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01244-19 · Cited by 107
“heavily immunosuppressed patients (116).”
Self-citationHuman Fungal Pathogens of Mucorales and Entomophthorales
Mendoza, L., Vilela, R., Voelz, K., Ibrahim, A. S., Voigt, K., & Lee, S. C. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019562 · Cited by 109
Self-citationUpdates in management of acute invasive fungal rhinosinusitis
Craig, J. R. (2019) · Current Opinion in Otolaryngology & Head & Neck Surgery · doi:10.1097/moo.0000000000000507 · Cited by 97
‘Ride on the ferrous wheel’ – The cycle of iron in macrophages in health and disease
Nairz, M., Schroll, A., Demetz, E., Tancevski, I., Theurl, I., & Weiss, G. (2015) · Immunobiology · doi:10.1016/j.imbio.2014.09.010 · Cited by 89
Gebremariam, T., Alkhazraji, S., Soliman, S. S. M., Gu, Y., Jeon, H. H., Zhang, L., French, S. W., Stevens, D. A., Edwards, J. E., Filler, S. G., et al. (2019) · Science Advances · doi:10.1126/sciadv.aaw1327 · Cited by 92
Self-citationJose, A., Singh, S., Roychoudhury, A., Kholakiya, Y., Arya, S., & Roychoudhury, S. (2021) · Journal of Maxillofacial and Oral Surgery · doi:10.1007/s12663-021-01604-2 · Cited by 92
“Iron chelators like deferasirox and deferiprone may prove to be beneficial in many clinical studies [21, 46, 47].”
BackgroundRecent Advances in the Pathogenesis of Mucormycoses
Petrikkos, G. L., & Tsioutis, C. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.03.009 · Cited by 97
Schmidt‐Hieber, M., Silling, G., Schalk, E., Heinz, W., Panse, J., Penack, O., Christopeit, M., Buchheidt, D., Meyding‐Lamadé, U., Hähnel, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw155 · Cited by 92
Ruhnke, M., Cornely, O. A., Schmidt‐Hieber, M., Alakel, N., Boell, B., Buchheidt, D., Christopeit, M., Hasenkamp, J., Heinz, W., Hentrich, M., et al. (2020) · Mycoses · doi:10.1111/myc.13082 · Cited by 88
Targeting iron assimilation to develop new antibacterials
Foley, T. L., & Simeonov, A. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.708335 · Cited by 82
An encapsulation of iron homeostasis and virulence in Cryptococcus neoformans
Kronstad, J. W., Hu, G., & Jung, W. H. (2013) · Trends in Microbiology · doi:10.1016/j.tim.2013.05.007 · Cited by 78
Bupha‐Intr, O., Butters, C. T., Reynolds, G. K., Kennedy, K., Meyer, W., Patil, S. S., Bryant, P. A., & Morrissey, C. O. (2021) · Internal Medicine Journal · doi:10.1111/imj.15592 · Cited by 82
Invasive Fungal Infections Secondary to Traumatic Injury
Kronen, R., Liang, S. Y., Bochicchio, G. V., Bochicchio, K. M., Powderly, W. G., & Spec, A. (2017) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2017.07.002 · Cited by 79
“Adjunctive deferasirox, which theoretically reduces fungal access to iron through its chelating ability and appeared promising in open-label studies, was actually associated with a higher 90-day mortality compared to placebo in a randomized controlled trial (Spellberg et al., 2012).”
BackgroundEfficacy of Liposomal Amphotericin B and Posaconazole in Intratracheal Models of Murine Mucormycosis
Luo, G., Gebremariam, T., Lee, H., French, S. W., Wiederhold, N. P., Patterson, T. F., Filler, S. G., & Ibrahim, A. S. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00313-13 · Cited by 73
“lates obtained from the DEFEAT Mucor clinical study (38).”
Self-citationTransferrin iron starvation therapy for lethal bacterial and fungal infections
Lin, L., Pantapalangkoor, P., Tan, B., Bruhn, K. W., Ho, T., Nielsen, T., Skaar, E. P., Zhang, Y., Bai, R., Wang, A., et al. (2014) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu049 · Cited by 68
Self-citationImmunomodulation as Therapy for Fungal Infection: Are We Closer?
Sam, Q. H., Yew, W. S., Seneviratne, C. J., Chang, M. W., & Chai, L. Y. A. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01612 · Cited by 68
“Unfortunately, statistical analysis showed that patients in the deferasirox arm of the trial were also more likely to have active malignancy, neutropenia and have received corticosteroid therapy, and patients given deferasirox had a higher mortality compared to the controls, which made interpretation of results inconc…”
BackgroundResultWhat Is New in Pulmonary Mucormycosis?
Danion, F., Coste, A., Hyaric, C. L., Melenotte, C., Lamoth, F., Calandra, T., Garcia‐Hermoso, D., Aimanianda, V., Lanternier, F., & Lortholary, O. (2023) · Journal of Fungi · doi:10.3390/jof9030307 · Cited by 66
Janjua, O. S., Shaikh, M. S., Fareed, M. A., Qureshi, S. M., Khan, M. I., Hashem, D., & Zafar, M. S. (2021) · Journal of Fungi · doi:10.3390/jof8010044 · Cited by 72
“The combination of deferasirox with liposomal amphotericin B has also been used as salvage therapy with promising results [58,68,189].”
BackgroundResultNew antifungal strategies: Drug combination and co-delivery
Zhu, P., Li, Y., Guo, T., Liu, S., Tancer, R. J., Hu, C., Zhao, C., Xue, C., & Liao, G. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114874 · Cited by 63
Future Directions in Mucormycosis Research
Kontoyiannis, D. P., Lewis, R. E., Lotholary, O., Spellberg, B. J., Πετρίκκος, Γ., Roilides, E., Ibrahim, A. S., & Walsh, T. J. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir886 · Cited by 56
Self-citationLewis, R. E., Albert, N. D., & Kontoyiannis, D. P. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03569-14 · Cited by 51
Self-citationModulation of Iron Metabolism in Response to Infection: Twists for All Tastes
Gomes, A. C., Moreira, A. C., Mesquita, G., & Gomes, M. S. (2018) · Pharmaceuticals · doi:10.3390/ph11030084 · Cited by 56
“However, chelators-based therapies have not been shown to be sufficiently effective in the treatment of infections in clinical trials [134,135].”
BackgroundDiabetes Mellitus and Infectious Diseases: Current Evidence and Clinical Implications
Kim, T., & Choi, S. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0508 · Cited by 62
“Although deferasirox, an iron chelator, showed synergistic benefit with liposomal amphotericin B in preclinical and small salvage cohorts [103], a randomized trial has demonstrated higher mortality with its use; however, it should be further investigational [104].”
Combination Therapy for Invasive Fungal Infections
Livengood, S. J., Drew, R. H., & Perfect, J. R. (2020) · Current Fungal Infection Reports · doi:10.1007/s12281-020-00369-4 · Cited by 54
Self-citationUpdate on therapeutic approaches for invasive fungal infections in adults
Boutin, C.-A., & Luong, M. (2024) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361231224980 · Cited by 54
Combination antifungal therapy for invasive fungal infections in children and adults
Hatipoğlu, N., & Hatipoğlu, H. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.13.29 · Cited by 58
“We are what we eat!” Invasive intestinal mucormycosis: A case report and review of the literature
Martinello, M., Nelson, A. J., Bignold, L. P., & Shaw, D. (2012) · Medical Mycology Case Reports · doi:10.1016/j.mmcr.2012.07.003 · Cited by 50
“Unfortunately, the Phase II Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) trial failed to demonstrate benefit in a randomized cohort of 20 patients with proven or probable mucormycosis [18].”
BackgroundRare fungal infectious agents: a lurking enemy
Skiada, A., Pavleas, I., & Drogari‐Apiranthitou, M. (2017) · F1000Research · doi:10.12688/f1000research.11124.1 · Cited by 53
“Combination of amphotericin B with deferasirox, an iron chelator which does not act as a siderophore for Mucorales , was associated with poorer outcomes in a small prospective study in patients with hematologic malignancies 134 .”
Fungal Infections of the Central Nervous System
Perfect, J. R. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407710-2.00046-1 · Cited by 49
Self-citationTransferrin-mediated iron sequestration as a novel therapy for bacterial and fungal infections
Bruhn, K. W., & Spellberg, B. (2015) · Current Opinion in Microbiology · doi:10.1016/j.mib.2015.07.005 · Cited by 48
Self-citationBiology, systematics, and clinical manifestations of Zygomycota infections
Muszewska, A., Pawłowska, J., & Krzyściak, P. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-014-2076-0 · Cited by 53
Agents of Mucormycosis and Entomophthoramycosis
Kontoyiannis, D. P., & Lewis, R. E. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00260-5 · Cited by 51
Self-citationEmerging Issues in Antifungal Resistance
Perfect, J. R., & Ghannoum, M. (2020) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2020.05.003 · Cited by 47
Self-citationStanford, F. A., & Voigt, K. (2020) · Genes · doi:10.3390/genes11111296 · Cited by 47
Host‐iron assimilation: pathogenesis and novel therapies of mucormycosis
Ibrahim, A. S. (2014) · Mycoses · doi:10.1111/myc.12232 · Cited by 46
Self-citationPCR methodology and applications for the detection of human fungal pathogens
McCarthy, M. W., & Walsh, T. J. (2016) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2016.1219253 · Cited by 47
“Mucormycosis, previously termed zygomycosis, is a rare and aggressive opportunistic infection caused by fungi belonging to the order Mucorales, including Mucor, Rhizopus, Rhizomucor, and Cunninghamella species [54,55].”
BackgroundRoilides, E., Antachopoulos, C., & Simitsopoulou, M. (2014) · Mycoses · doi:10.1111/myc.12236 · Cited by 46
Antifungal combinations in Mucorales: A microbiological perspective
Schwarz, P., Cornely, O. A., & Dannaoui, E. (2019) · Mycoses · doi:10.1111/myc.12909 · Cited by 43
Pomorska, A., Małecka, A., Jaworski, R., Radoń‐Proskura, J., Hare, R. K., Nielsen, H. V., Andersen, L. O., Jensen, H. E., Arendrup, M. C., & Irga‐Jaworska, N. (2018) · Mycopathologia · doi:10.1007/s11046-018-0287-0 · Cited by 42
Mucormycosis in a Renal Transplant Recipient: Case Report and Comprehensive Review of Literature
Hamdi, T., Karthikeyan, V., & Alangaden, G. J. (2014) · International Journal of Nephrology · doi:10.1155/2014/950643 · Cited by 41
“However, a small clinical trial of 20 patients (DEFEAT Mucor Study) using LAmB and deferasirox demonstrated worse outcomes in the deferasirox arm [56].”
BackgroundPaiva, J. A., & Pereira, J. M. (2013) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32835ebcb7 · Cited by 40
How to treat fungal infections in ICU patients
Matthaiou, D. K., Christodoulopoulou, T. C., & Dimοpoulos, G. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-0934-8 · Cited by 44
“mucormycosis [74].”
Hsu, J. L., Manouvakhova, O. V., Clemons, K. V., Inayathullah, M., Tu, A. B., Sobel, R. A., Tian, A., Nazik, H., Pothineni, V. R., Pasupneti, S., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aag2616 · Cited by 38
Metadata
- Authors
- Spellberg, B., Ibrahim, A. S., Chin-Hong, P. V., Kontoyiannis, D. P., Morris, M. I., Perfect, J. R., Fredricks, D., & Brass, E. P.
- Affiliations
- University of California, Los Angeles (US)
- University of California, San Francisco (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Miami (US)
- Duke Medical Center (US)
- University of Washington (US)
- Corresponding author
- Spellberg, Brad
- ORCID
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-09-20
- Volume
- 67
- Issue
- 3
- Pages
- 715-722
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- PMC
- PMC3383100
- OpenAlex
- W2116858171
- Cited by
- 308
- References
- 32
- Citations by year
- 2026: 13 · 2025: 15 · 2024: 9 · 2023: 22 · 2022: 24 · 2021: 30 · 2020: 16 · 2019: 20 · 2018: 22 · 2017: 16 · 2016: 22 · 2015: 17 · 2014: 33 · 2013: 25 · 2012: 19
- FWCI
- 17.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Antimicrobial Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Gilead Sciences
- Astellas Pharma
- National Institutes of Health (UL1TR000124)
- National Institute of Allergy and Infectious Diseases (R01AI081719, R01AI063503)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Mycology
- Keywords
- mucormycosis, deferasirox, liposomal amphotericin B, iron chelation, adjunctive therapy, mortality, treatment safety
- MeSH terms
- Deferasirox, Adult, Aged, Amphotericin B, Animals, Antifungal Agents, Benzoates, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Iron Chelating Agents, Male, Middle Aged, Mucormycosis, Placebos, Triazoles, Survival Analysis, Treatment Outcome, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.